

Centre
international
de TB McGill



McGill
International
TB Centre

A PAHO/WHO Collaborating Centre for Tuberculosis Research



Dr. Tom Scriba, PhD

Professor Tom Scriba (PhD) is Deputy Director, Immunology at the South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, where he directs the clinical immunology laboratory. He trained in biological sciences at Stellenbosch University in South Africa and obtained a DPhil (PhD) in T cell Immunology at Oxford University, UK. He returned to South Africa in 2006 to complete a postdoctoral fellowship in paediatric and clinical immunology in TB and vaccinology at the Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town. Dr Scriba's research focuses on TB vaccine development, immunopathogenesis of *M. tuberculosis* infection as well as development of biomarkers of key transition points between the clinical stages of *M. tuberculosis* infection and disease. Dr Scriba's research is funded by competitive grants from the Bill and Melinda Gates Foundation, European Developing Countries Clinical Trials Partnership, South African Medical Research Foundation, US National Institutes of Health and the European Union.

TB Seminar

Friday, Feb. 5, 2021

Time: **2:30 – 3:30 PM**

Please note that this seminar will be 60 minutes.

By **Zoom**:

Meeting ID: 814 301 0609

Passcode: 91SDws

Lessons learnt from the correlate of risk-targeted intervention study (CORTIS)

Targeted preventive therapy for individuals at highest risk of incident TB might impact the global TB epidemic by interrupting transmission. We tested performance of a transcriptomic signature of TB (RISK11) in adult volunteers recruited at five communities in South Africa, and efficacy of RISK11 signature-guided preventive therapy, in parallel, using a hybrid three-group study design, in the CORTIS trial.

This talk will discuss the results of the trial as well as those of a parallel observational study in people living with HIV. It will highlight novel insights from longitudinal RISK11 signature trajectories and the effects of respiratory infections on RISK11 signature results and TB progression.

www.mcgill.ca/tb/